Cost-Effectiveness Analysis of Rizatriptan and Sumatriptan versus Cafergot ® in the Acute Treatment of Migraine

ISSN： 1172-7047

Source： CNS Drugs, Vol.19, Iss.7, 2005-01, pp. : 635-642

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-Effectiveness Analysis of Stratified Versus Stepped Care Strategies for Acute Treatment of Migraine: The Disability in Strategies for Care (DISC) Study

By Sculpher M.

PharmacoEconomics, Vol. 20, Iss. 2, 2002-02 ,pp. : 91-100

Adis International

Access to resources Recommend Favorite

Proton Pump Inhibitors in Acute Treatment of Reflux Oesophagitis: A Cost-Effectiveness Analysis

By Lucioni C.

Clinical Drug Investigation, Vol. 25, Iss. 5, 2005-01 ,pp. : 325-336

Adis International

Access to resources Recommend Favorite

Rizatriptan, sumatriptan beat caffeine/ergotamine for migraine

Inpharma, Vol. 1, Iss. 1499, 2005-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Rizatriptan: A Pharmacoeconomic Review of its Use in the Acute Treatment of Migraine

By McCormack Paul L. Foster Rachel H.

PharmacoEconomics, Vol. 23, Iss. 12, 2005-01 ,pp. : 1283-1298

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Enoxaparin versus Unfractionated Heparin in the Secondary Prevention of Acute Coronary Syndrome

By Brosa M.

PharmacoEconomics, Vol. 20, Iss. 14, 2002-01 ,pp. : 979-987

Adis International

Access to resources Recommend Favorite